Sign Up Today and Learn More About PathAI Stock
Invest in or calculate the value of your shares in PathAI or other pre-IPO companies through EquityZen's platform.
PathAI Stock (PAHI)
PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.
About PathAI Stock
Founded
2016
Headquarters
Boston, MA, US
Industries
Content and Publishing, Messaging and Telecommunications, Sports
PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
PathAI Press Mentions
Stay in the know about the latest news on PathAI
Expanding the dna mismatch repair deficiency/microsatellite instability …
patents • May 04, 2025
Additive multiple instance learning
patents • May 04, 2025
PathAI to Present at Digestive Disease Week
globenewswire • Apr 30, 2025
24 Best AI Tools for Boosting Your Productivity in 2025
techtimes • Apr 26, 2025
The Healthcare Technology Report Announces The Top 25 Healthcare AI Companies of 2025
prweb • Apr 24, 2025
Investors in PathAI
Discover investors in PathAI stock and explore their portfolio companies
PathAI Management
Leadership team at PathAI
Co-founder & CEO
Andrew Beck
Co-founder & CTO
Aditya Khosla
Join now and verify your accreditation status to gain access to:
- PathAI Current Valuation
- PathAI Stock Price
- PathAI Management
- Available deals in PathAI and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- PathAI Cap Table and Funding History by Share Class and Liquidity Preferences
- PathAI Revenue and Financials
- PathAI Highlights
- PathAI Business Model
- PathAI Risk Factors
- PathAI Research Report from SACRA Research
Trading PathAI Stock
How to invest in PathAI stock?
Accredited investors can buy pre-IPO stock in companies like PathAI through EquityZen funds. These investments are made available by existing PathAI shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell PathAI stock?
Shareholders can sell their PathAI stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
